Innoviva, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $411.3M | $358.7M | $310.5M | $331.3M | $391.9M |
| Gross profit | $307.7M | $296.2M | $246.0M | — | — |
| Selling, general & administrative | $113.3M | $115.7M | $98.2M | $63.5M | $16.2M |
| Research and development | $30.6M | $13.7M | $33.9M | $41.4M | $576,000 |
| Operating expenses | $143.9M | $129.3M | $132.2M | — | $16.8M |
| Operating income | $163.7M | $166.9M | $113.9M | — | $375.1M |
| Interest expense | $16.7M | $22.2M | $19.2M | $15.8M | $19.1M |
| Pretax income | $326.9M | $37.4M | $194.1M | $286.9M | $445.3M |
| Income tax expense | $55.7M | $14.0M | $14.4M | $66.7M | $76.4M |
| Net income | $271.2M | $23.4M | $179.7M | $220.3M | $368.8M |
| Balance Sheet | |||||
| Cash and equivalents | $550.9M | $305.0M | $193.5M | $291.0M | $201.5M |
| Current assets | $727.5M | $554.3M | $344.2M | $443.5M | $313.7M |
| Total assets | $1.6B | $1.3B | $1.2B | $1.2B | $926.4M |
| Current liabilities | $49.7M | $236.1M | $38.1M | $135.0M | $5.8M |
| Total debt | $257.7M | $448.3M | $446.2M | $540.4M | $394.7M |
| Stockholders' equity | $1.2B | $691.2M | $675.0M | $565.8M | $414.7M |
| Cash Flow Statement | |||||
| Cash from operations | $196.9M | $188.7M | $141.1M | $201.7M | $363.8M |
| Depreciation and amortization | — | — | — | — | $13.8M |
| Stock-based compensation | $9.5M | $6.4M | $5.8M | $7.3M | $2.0M |
| Capital expenditure | $1.1M | $270,000 | $411,000 | $67,000 | $0 |
| Free cash flow | $195.8M | $188.4M | $140.7M | $201.7M | $363.8M |
| Dividends paid | — | — | — | — | $0 |
| Share repurchases | $4.5M | $14.8M | $75.7M | $8.5M | $394.1M |
| Impairments | $0 | $0 | $0 | — | — |
Shares outstanding 73.8M · Free float 11.3%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.